{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:36:44Z","timestamp":1722559004446},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.7759\/cureus.65884","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:25:14Z","timestamp":1722471914000},"source":"Crossref","is-referenced-by-count":0,"title":["Flecainide Toxicity From Clinical Pharmacology Perspectives"],"prefix":"10.7759","author":[{"given":"Naoyuki","family":"Otani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0138","article-title":"Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - digest version","volume":"81","author":"Aonuma K","year":"2017","unstructured":"Aonuma K, Shiga T, Atarashi H, et al.. Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - digest version. Circ J. 2017, 81:581-612. 10.1253\/circj.CJ-66-0138","journal-title":"Circ J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(84)90501-0","article-title":"Metabolism of flecainide","volume":"53","author":"Conard GJ","year":"1984","unstructured":"Conard GJ, Ober RE. Metabolism of flecainide. Am J Cardiol. 1984, 53:41-51. 10.1016\/0002-9149(84)90501-0","journal-title":"Am J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03142.x","article-title":"Oral flecainide pharmacokinetics in patients with impaired renal function","volume":"28","author":"Forland SC","year":"1988","unstructured":"Forland SC, Burgess E, Blair AD, et al.. Oral flecainide pharmacokinetics in patients with impaired renal function. J Clin Pharmacol. 1988, 28:259-67. 10.1002\/j.1552-4604.1988.tb03142.x","journal-title":"J Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13560","article-title":"CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients","volume":"128","author":"Sasaki T","year":"2021","unstructured":"Sasaki T, Yasui-Furukori N, Komahashi-Sasaki H, et al.. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients. Basic Clin Pharmacol Toxicol. 2021, 128:677-85. 10.1111\/bcpt.13560","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00209.x","article-title":"Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes","volume":"50","author":"Kubota T","year":"2000","unstructured":"Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000, 50:31-4. 10.1046\/j.1365-2125.2000.00209.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.195","article-title":"Pharmacokinetics of flecainide in patients with cirrhosis of the liver","volume":"44","author":"McQuinn RL","year":"1988","unstructured":"McQuinn RL, Pentik\u00e4inen PJ, Chang SF, Conard GJ. Pharmacokinetics of flecainide in patients with cirrhosis of the liver. Clin Pharmacol Ther. 1988, 44:566-72. 10.1038\/clpt.1988.195","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450 - mediated metabolism","volume":"80","author":"Frye RF","year":"2006","unstructured":"Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch RA. Liver disease selectively modulates cytochrome P450 - mediated metabolism. Clin Pharmacol Ther. 2006, 80:235-45. 10.1016\/j.clpt.2006.05.006","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276272-flecainide-toxicity-from-clinical-pharmacology-perspectives","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:25:17Z","timestamp":1722471917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276272-flecainide-toxicity-from-clinical-pharmacology-perspectives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.65884","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}